PIK3R3 and neoplasm: Garcia and colleagues focused on the screening and effects of specific mutations like CARD11‐PIK3R3 and their impact on T‐cell signaling and anti‐tumor efficacy, providing clinically applicable novel solutions for improving T‐cell therapy and strategies to avoid irAEs.1